JPS5843913A - Production of fatty ointment containing steroidal active ingredient - Google Patents

Production of fatty ointment containing steroidal active ingredient

Info

Publication number
JPS5843913A
JPS5843913A JP14290281A JP14290281A JPS5843913A JP S5843913 A JPS5843913 A JP S5843913A JP 14290281 A JP14290281 A JP 14290281A JP 14290281 A JP14290281 A JP 14290281A JP S5843913 A JPS5843913 A JP S5843913A
Authority
JP
Japan
Prior art keywords
ointment
solvent
fatty
oil
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP14290281A
Other languages
Japanese (ja)
Inventor
Takeshi Kaguma
鹿熊 武
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IKEDA MOHANDOU KK
Original Assignee
IKEDA MOHANDOU KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IKEDA MOHANDOU KK filed Critical IKEDA MOHANDOU KK
Priority to JP14290281A priority Critical patent/JPS5843913A/en
Publication of JPS5843913A publication Critical patent/JPS5843913A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE:When a fatty ointment containing steroids as active ingredients is prepared, hydroxyethyl salicylate is used as a solvent, thus permitting the production of the above stabilized and less skin-irritating ointment through simple operations. CONSTITUTION:Hydroxyethyl salicylate of the formula is used as a solvent and a steroid preparation such as betamethasone valerate is dissolved in the solvent. When necessary, an oil-soluble solvent such as isocetanol is added to increase the compatibility between the above solvent and the solid to semisolid ointment base. Then, the resultant solution is mixed with the fatty solid ointment base under heating by a usual method to give the objective fatty ointment containing steroids. The addition of the above solvent facilitates the preparation of ointment and cream, improves the percutaneous absorption, stability and skin irritation of the ointment and increases the analgesic and antiinflammatory effect.

Description

【発明の詳細な説明】 法に関するものである。[Detailed description of the invention] It is about law.

従来、ステロイド糸条ケ配合した製剤、%に油脂性状,
責の製造に於いて、液状界面活性剤を用いて油脂性基剤
に配合する方法ならびに溶媒?,用いて油脂性基剤に配
合する方法が採用さ゛れて、い、た。
Conventionally, preparations containing steroid threads, oil and fat properties,
How to blend a liquid surfactant into an oleaginous base and a solvent in the production of a liquid surfactant? A method of blending into an oleaginous base using

しかしながら、前者の場合においては皮膚に対する刺激
が強くその上経時的にステロイド糸条の結晶が析出し、
製品としては十分満足するものではなかった。
However, in the former case, the irritation to the skin is strong, and steroid thread crystals precipitate over time.
The product was not completely satisfactory.

また、雛媒として、、油俗性給媒ケ用いた場合、例えば
イノセタノール、スクワラン、一りテルドデカノールケ
用いた時には、これらの溶媒の一ステロイド系楽に対す
る浴解度が低いため掻量配合しな&tt’Lばならず、
油)l¥5性軟貴剤の場合、ワセリンのような半固形成
分と成体成分が分離し易く、かつ反騰刺激性が強くなる
という難点があった。また、、#1媒として水浴性のM
慎浴媒を用いた揚廿・94 j Fi 7’ロピレング
リコール、ポリエチレングリコールヶ用いた時には、こ
れらの溶媒は主桑の経皮吸収性?低下させるとと4に皮
膚刺激性が強く、かつ油脂性軟膏の場合には、油脂成分
との相溶性がないため製造上両者・を配合すること1[
しく、かつ配合しても分離し易いという鮭点があった。
In addition, when oil-based carriers are used as brood media, such as inocetanol, squalane, or teldodecanol, these solvents have low bath solubility for monosteroids, so the amount of water is reduced. Don't mix &tt'L,
In the case of oil-based softeners, the semi-solid component such as petrolatum and the adult component tend to separate, and the problem is that the rebound irritation is strong. In addition, as #1 medium, water-bathable M
94 J Fi 7' When using a bathing medium such as propylene glycol or polyethylene glycol, are these solvents transdermal absorbable? If it is lowered, it is highly irritating to the skin, and in the case of oil-based ointments, it is not compatible with oil and fat components, so it is necessary to mix both in production.
Salmon's advantage was that it was easy to separate even when blended.

そこで不発明番らはこれらの欠点を解消するため、特に
皮JfII刺激性のない、安定なステロイド糸条の油脂
性軟膏に44する目的で鋭意研91した結果、サリチル
酸エチレングリコールがステロイド糸条に対し極めて高
い溶解度を有し、しかも油脂性基剤と比較的相溶性がよ
いことを見い出し不発明を完成するに至り良。
Therefore, in order to eliminate these drawbacks, Fubenban et al. carried out extensive research91 with the aim of creating a stable steroid thread oil-based ointment that was not particularly irritating to the skin and found that ethylene glycol salicylate was added to the steroid thread. However, he discovered that it has extremely high solubility and relatively good compatibility with oil-based bases, and completed his invention.

Mtlち、本発明はステロイド糸条を1桑として油脂性
軟膏を製造するにあたり、溶媒としてサリチル酸エチレ
ングリコールを用いることに特徴とするステロイド糸条
配合の油脂性軟膏の製法に関するものである。
Mtl. The present invention relates to a method for producing an oleaginous ointment containing steroid threads, which is characterized in that ethylene glycol salicylate is used as a solvent in producing the oleaginous ointment using one mulberry of steroid threads.

本発明により製造操作が容易でしかも皮膚刺激性の弱い
、安定な油脂性軟膏に得ることが可能になった。
The present invention has made it possible to obtain a stable oil-based ointment that is easy to manufacture and has low skin irritation.

本発明に用いるステロイド糸条としては、吉草酸ペタメ
タシン、fロビオン酸ベクロメタゾン、酢酸ヒドロコル
チゾン、グレドニゾロン、トリアムシノロンアセトニド
、フルオロメトロン、フルランドレノロン等が埜げられ
る。
Examples of the steroid thread used in the present invention include petamethacin valerate, beclomethasone f-lobionate, hydrocortisone acetate, glednisolone, triamcinolone acetonide, fluorometholone, flurandrenolone, and the like.

不発明に用いるサリチル酸エチレングリコール妓、 の徊造式管有する沸点/AV”C〜/り0℃(/コrr
mH/)の無色粘桐の液体であp比重α:0約l、コS
O1有し、消炎鎮痛作用tもつ物質である。
Ethylene glycol salicylate used in the invention has a boiling point /AV"C ~ /0℃ (/corrr
mH/) colorless viscous paulownia liquid with p specific gravity α: 0 approx.
It is a substance with O1 and anti-inflammatory analgesic effect.

以下、本発明のm Ili#性軟貴の製法について説明
する。
Hereinafter, the method for producing the mIli# soft material of the present invention will be explained.

まず生薬であ−るステロイド系薬?サリチル酸工fL/
7グリコールに俗解する。この場合、使用するステロイ
ド糸条の倉ハ、サリチル酸グリコールに光分溶解する飯
である。例えば、吉草酸ベタメタシンの場合は、サリチ
ル酸エチレングリコール/ mlに対し、吉草酸ベタメ
タシン0.I29、グロピオン酸ベクロメタゾンの場合
は、サリチル酸エチレングリコールQ 、 g yil
に対しグロピオン酸ペクロメタゾン0 、02 !; 
)’以下の適宜の量の桑が溶解する。尚、必費により、
従来使用さnている油溶性温媒、例えばイソセタノール
、スクワラン尋の使用量′に適宜調節してサリチル酸エ
チレングリコールと併用し、サリチル酸エチレングリコ
ールと固形基剤及び半固形基剤の相溶性ケ高めることが
できる。
First of all, is it a steroid drug that is a crude drug? salicylic acid fL/
7 Glycol is commonly understood. In this case, the steroid thread used is photodissolved in glycol salicylate. For example, in the case of betamethacin valerate, 0.0% betamethacin valerate per ml ethylene glycol salicylate. I29, for beclomethasone gropionate, ethylene glycol Q salicylate, g yil
vs. peclomethasone gropionate 0,02! ;
) 'The following appropriate amount of mulberry is dissolved. In addition, due to necessary expenses,
The amount of conventionally used oil-soluble heating media, such as isosetanol and squalane, is adjusted appropriately and used in combination with ethylene glycol salicylate to increase the compatibility between ethylene glycol salicylate and solid bases and semi-solid bases. be able to.

次に、このステロイド糸条の旙液を油脂性1形基剤、例
えば油脂類(ミツロウ、rイロウ、ラノリン等)、炭化
水累@(流動I4ラフイン、固形)9ラフイン、ワセリ
ン、スクワラン等)、高級脂肪酸類()臂ルミチン酸、
ステアリンi1等)、−級アルコール類(セタノール、
ステアリルアルコール等)、エステル類(叱りステン敏
イノプロピル、乳酸セチル等)と、常法により加温混合
して油II盲性軟臂とする。
Next, the steroid thread liquid is added to an oil-based type 1 base, such as oils and fats (beeswax, yellow wax, lanolin, etc.), hydrocarbon mixture (fluid I4 rough-in, solid) 9 rough-in, vaseline, squalane, etc.) , higher fatty acids ()lumitic acid,
stearin i1 etc.), -grade alcohols (cetanol,
Stearyl alcohol, etc.) and esters (such as inopropyl lactate, cetyl lactate, etc.) are heated and mixed in a conventional manner to obtain an oil II blind flexure.

以上の如くして、不発明の方法により得られた油s性軟
貴は、サリチル酸エチレングリコールのステロイド系薬
に対する溶解度が高いのて軟膏・クリームの1製が容易
である。またサリチル酸エチレングリコールri経皮吸
収性が優れているため、ステロイド糸条の軽灰吸収性が
著しく改善された。
As described above, the oily ointment obtained by the uninvented method has a high solubility in steroid drugs of ethylene glycol salicylate, so that it can be easily made into an ointment or cream. Furthermore, since ethylene glycol salicylate ri has excellent transdermal absorption, the light ash absorption of the steroid thread was significantly improved.

また、サリチル酸エチレングリコールは油浴性であるた
め、他の固形、敵状の油脂基剤との相溶性がよく、軟膏
剤の安定性が改善された。
In addition, since ethylene glycol salicylate is oil bath-compatible, it has good compatibility with other solid and hostile oil bases, and the stability of the ointment was improved.

更にサリチル酸エチレングリコールは皮膚刺激性が弱い
ものであるため、従来のこの棟の軟膏の如く皮膚刺激性
の伽い溶媒を用いることがないから皮膚刺激性が著しく
軽減できた。
Furthermore, since ethylene glycol salicylate has weak skin irritation, it does not use a solvent that is highly irritating to the skin, as is the case with conventional ointments, and the skin irritation can be significantly reduced.

加、tて、サリチル酸エチレングリコールはそn自体が
消炎鎮痛作用?mするため、主桑のステロイド糸条と共
に10炎績痛の効果を増強することができる等の多くの
利点がある。
Also, does ethylene glycol salicylate itself have anti-inflammatory and analgesic effects? Therefore, it has many advantages such as being able to enhance the effect of 10 inflammation pain along with the main mulberry steroid thread.

以下、実施例に工り不発明rI!に詳細に説明する。The following is an example of the invention! will be explained in detail.

実施例/ サリチル酸エチレングリコールθ、jl、イソセタノー
ルg、ot、マイクロクリスタリンワックス3.0?、
白色ワセリンざl、、’173ft秤量し、200m1
のビーカーに入れ、これに精神したプロピオン酸ペクロ
メタゾンo、oas’tw加え・水浴中ざθ℃前猿で溶
解攪拌し均質にした後、水浴より取、石出し室温まで冷
却し半固体とし油脂性軟膏倉得た。
Example/Ethylene glycol salicylate θ, jl, isosetanol g, ot, microcrystalline wax 3.0? ,
White petrolatum, weighing 173ft, 200m1
Pour it into a beaker, add the distilled beclomethasone propionate, oas'tw, and dissolve it in a water bath at θ℃. Stir to make it homogeneous, then remove it from the water bath, remove the stone, cool it to room temperature, and make it semi-solid and oily. I got the ointment.

実施例コ サリチル酸エチレングリコールθ1g?、イソセタノー
ルt、Of、マイクロクリスタリンワックスS、Ot、
白色ワセリンgt 、ogvr秤重し、200114の
ビーカーに入れ、これに精秤した吉草酸ペタメタシン0
./コ?ケ加え、水温中gO℃前後で溶解攪拌し均質に
した後、水浴より取り出し、室温゛まで放冷し半(支)
体として油脂性軟膏1得た。
Example: Ethylene glycol cosalicylate θ1g? , isosetanol t, Of, microcrystalline wax S, Ot,
White petrolatum gt, weighed on an ogvr scale, placed in a 200114 beaker, and petamethacin valerate 0 was accurately weighed into this.
.. /Ko? After adding it to the water temperature and stirring to make it homogeneous at around gO ℃, remove it from the water bath and leave it to cool to room temperature.
One oily ointment was obtained for the body.

実施例3 本実施例は実施例1及び実施例λで得られfc?11脂
性軟賃脂性軟状縮作用を示すものである。
Example 3 This example was obtained from Example 1 and Example λ, and fc? 11 shows a fatty softening action.

マツケンジー(Mckenzl@)等アーカイフデルマ
トロギイ(^rch、Derm ) 、31.巻、60
g頁、/q4コ年に曹ビ叔の方法に準じた方法により本
試験ケ行った。即ち、健康成人男子10名の上背部に下
記試料^、B、C,D’i各々貼付し、血管収縮作用を
金白現象として評価、判定し走。
Kenzie Matsu (McKenzl@) et al. Archive Dermatology (^rch, Derm), 31. Volume, 60
This test was carried out in 2013 by a method similar to that of Cao Bishu. That is, the following samples ^, B, C, and D'i were applied to the upper backs of 10 healthy male adults, and the vasoconstriction effect was evaluated and determined as the Kinpaku phenomenon.

この判定は全く無反応1−(−)、軽度の蒼白化ケ(±
)、明らか一&R白化會(+)とした。
This judgment is 1-(-) with no reaction at all, slight pallor (±
), clearly one & R whitening meeting (+).

試料^:実施例1で#!造した軟膏 、B:実施例/でサリチル酸エチレングリコール?商い
て製造さ几た軟膏 C:実施例コで製造した軟膏 D=実実施ココサリチル酸エチレングリコール倉除いて
製造された軟膏 賦科除去一時IiJ後の血管収縮作用の陽性率を測定し
、結果を表/にボす。
Sample ^: # in Example 1! Ointment B: Example/Ethylene glycol salicylate? Commercially manufactured ointment C: Ointment D manufactured in Example C = Actual implementation Ointment manufactured by removing cocosalicylic acid ethylene glycol Put it on the table.

実施例ダ 本実施例は実施例1及び実施例−で製造された油脂性軟
膏の皮膚刺赦性の試験例を示すものである。
EXAMPLE This example shows a test example of the skin stinging properties of the oily ointments produced in Example 1 and Example 2.

本試験はノ臂ツチテストにより検討した。すなわち、健
康成人男子70名の上背部に実施例3と同じ試料にダに
時間クローズドパッチし、/4ツチ絆除去/時間後とラ
ダ時間後に皮屑刺激性の程&?判定した。試験結果r表
λに示す。
This test was conducted using the Nobutsuchi test. That is, the same sample as in Example 3 was patched on the upper backs of 70 healthy male adults for a period of 4 hours, and the degree of irritation to skin dandruff was observed after 4 hours and after 4 hours. I judged it. The test results are shown in Table λ.

尚、判定、基準は本邦における本葉に従った。In addition, the judgment and criteria were in accordance with the original Japanese standard.

無反応      (−) 0点 わずかな紅斑   (±>O,S点 明らかな紅斑   (+)7点 紅斑+丘棲又は浮腫(++)  一点 と評点し刺撤指at前記の式から算出した。No response (-) 0 points Slight erythema (±>O, S points Obvious erythema (+) 7 points Erythema + papules or edema (++) 1 point The score was calculated using the above formula.

除去/時間後又は2’1時間後のより反応全例数 表  − 表/及び表コよシ明らかな通り、本発明の方法により得
られた油脂性軟膏は血管゛収縮作用が優九しかも皮膚刺
激性の弱いものであった。
As is clear from the table and table, the oil-based ointment obtained by the method of the present invention has an excellent vasoconstrictive effect and a skin-constricting effect. It was a weak irritant.

Claims (1)

【特許請求の範囲】[Claims] ステロイド糸条を主薬として油脂性軟膏ケ製造するにあ
たり溶媒としてサリチル酸エチレングリコールケ用いる
こと′?を特徴とする、ステロイド差薬配合の油脂性軟
膏の製法。
Is it possible to use ethylene glycol salicylate as a solvent when manufacturing an oil-based ointment using steroid thread as the main ingredient? A method for producing an oil-based ointment containing steroids, characterized by:
JP14290281A 1981-09-10 1981-09-10 Production of fatty ointment containing steroidal active ingredient Pending JPS5843913A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP14290281A JPS5843913A (en) 1981-09-10 1981-09-10 Production of fatty ointment containing steroidal active ingredient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14290281A JPS5843913A (en) 1981-09-10 1981-09-10 Production of fatty ointment containing steroidal active ingredient

Publications (1)

Publication Number Publication Date
JPS5843913A true JPS5843913A (en) 1983-03-14

Family

ID=15326256

Family Applications (1)

Application Number Title Priority Date Filing Date
JP14290281A Pending JPS5843913A (en) 1981-09-10 1981-09-10 Production of fatty ointment containing steroidal active ingredient

Country Status (1)

Country Link
JP (1) JPS5843913A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62149620A (en) * 1985-09-26 1987-07-03 Shionogi & Co Ltd Analgesic antiinflammatory for external use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51148037A (en) * 1975-05-11 1976-12-18 Dso Pharmachim Treating agent for old man nature alopecia
JPS5446818A (en) * 1977-09-21 1979-04-13 Lion Dentifrice Co Ltd Surgical antiiinflammatory and anodyne agent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51148037A (en) * 1975-05-11 1976-12-18 Dso Pharmachim Treating agent for old man nature alopecia
JPS5446818A (en) * 1977-09-21 1979-04-13 Lion Dentifrice Co Ltd Surgical antiiinflammatory and anodyne agent

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62149620A (en) * 1985-09-26 1987-07-03 Shionogi & Co Ltd Analgesic antiinflammatory for external use

Similar Documents

Publication Publication Date Title
US5061700A (en) Glyceryl acetate ointment vehicles
US5612327A (en) 1α,24-(OH)2 -cholecalciferol emulsion composition and method for treating psoriasis
US4048310A (en) Topical steroid formulation in form of lotion or cream
JPH0729929B2 (en) Cream containing hydrocortisone diester
EP0084341B2 (en) Emulsion-type composition for external use
EP0020117A2 (en) Corticosteroid formulations containing sebacate carrier
US2431558A (en) Vasodilator compositions comprising alkyl nicotinates
JPH0459292B2 (en)
FR2491333A1 (en) TOPICALLY ADMINISTRATIVE PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-INFLAMMATORY STEROIDS
US4346086A (en) Corticosteroid-containing cream
JPH0676328B2 (en) Steroid cream formulation
JPS6186940A (en) Oil in water type emulsion composition
JPH0413624A (en) Pyroxycam-containing pharmaceutical composition for topical application
JPS5843913A (en) Production of fatty ointment containing steroidal active ingredient
JPS61204109A (en) Emulsion-type composition for external use
JPS5933211A (en) Oleaginous ointment
JPH05331066A (en) Composition for treatment of acne vulgaris
RU2233152C1 (en) Anti-inflammatory and anti-itching cream for treatment of dermatological disease
JPS589081B2 (en) Vehicle composition
JP3174590B2 (en) Steroid ointment
JPH0140806B2 (en)
US4496554A (en) Oleaginous emollient vehicle for steroid formulations
JPS6140203B2 (en)
JPH06271420A (en) Water absorption improver for cosmetics and skin external drugs
JPH06264049A (en) Consistency improver for cosmetics or for external preparation for skin